Evidence map›Paper›PMID 36975736›Full record

ArticleHematology reports2023

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.

Ruxandra Irimia, Sinziana Barbu, Codruta Popa, Sorina Badelita

Open access · goldFull text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ruxandra IrimiaSchool of Medicine, "Carol Davila" University of Medicine and Pharmacy, 4192910 Bucharest, Romania.
Sinziana BarbuSchool of Medicine, "Carol Davila" University of Medicine and Pharmacy, 4192910 Bucharest, Romania.
Codruta PopaSchool of Medicine, "Carol Davila" University of Medicine and Pharmacy, 4192910 Bucharest, Romania.
Sorina BadelitaFundeni Clinical Institute, 4192910 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROInstitutul Clinic Fundeni · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin's Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin.

Indexed as

autoimmune hemolytic anemiaautoimmune thrombocytopeniaBrentuximab VedotinEvans syndromeperipheral T cell lymphoma

Identifiers

PMID36975736
PMCPMC10048708
OpenAlexW4353064278

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read19
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.